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Abstract
Background: Psychiatric patients often require chronic treatment with antipsychotic drugs, and while rats are frequently
used to study antipsychotic-induced metabolic adverse effects, long-term exposure has only partially mimicked the
appetite-stimulating and weight-inducing effects found in the clinical setting. Antipsychotic-induced effects on serum lipids
are also inconsistent in rats, but in a recent study we demonstrated that subchronic treatment with the orexigenic
antipsychotic olanzapine resulted in weight-independent increase in serum triglycerides and activation of lipogenic gene
expression in female rats. In addition, a recent long-term study in male rats showed that chronic treatment with
antipsychotic drugs induced dyslipidemic effects, despite the lack of weight gain.
Aims: In the current study, we sought to examine long-term effects of antipsychotic drugs on weight gain, lipid levels and
lipid composition after twice-daily administration of antipsychotics to female rats, and to investigate potential beneficial
effects of the lipid-lowering agent tetradecylthioacetic acid (TTA), a modified fatty acid.
Methods: Female rats were exposed to orexigenic antipsychotics (olanzapine or clozapine), metabolically neutral
antipsychotics (aripiprazole or ziprasidone), or TTA for 8 weeks. Separate groups received a combination of clozapine and
TTA or olanzapine and TTA. The effects of TTA and the combination of olanzapine and TTA after 2 weeks were also
investigated.
Results: The antipsychotic-induced weight gain and serum triglyceride increase observed in the subchronic setting was not
present after 8 weeks of treatment with antipsychotics, while lipid-lowering effect of TTA was much more pronounced in
the chronic than in the subchronic setting, with concomitant upregulation of key oxidative enzymes in the liver.
Unexpectedly, TTA potentiated weight gain in rats treated with antipsychotics.
Conclusion: TTA is a promising candidate for prophylactic treatment of antipsychotic-induced dyslipidemic effects, but a
more valid long-term rat model for antipsychotic-induced metabolic adverse effects is required.
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Introduction
The second-generation antipsychotics clozapine (CLZ) and
olanzapine (OLZ), arguably the most efficacious pharmacological
agents presently recognized for positive symptoms of schizophre-
nia [1], induce serious metabolic adverse effects such as weight
gain, dyslipidemia and glucose dysregulation in patients
[2,3,4,5,6,7,8]. Rodent models are frequently used to study
antipsychotic adverse effects, with glucose dysregulation consis-
tently reproduced in female and male rats after treatment with
both OLZ and CLZ [9,10,11,12]. Increased food intake (hyper-
phagia) and weight gain is evident in female rats treated with OLZ
[7,13,14,15,16], but not with CLZ [17,18,19], although both
drugs have orexigenic (appetite-stimulating) potential in the
clinical setting [5]. The number of studies concerning the influence
of antipsychotic agents on serum lipids is limited in rodents, and
the findings have been inconsistent [15,20,21,22]. Recently,
however, we repeatedly demonstrated that two weeks of twice-
daily oral administration of a constant dose of OLZ (6 mg/kg)
elevated fasting serum triglycerides (TG) in female rats [23].
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Interestingly, increased serum TG levels were observed both in ad
libitum-fed rats that gained weight and in food-restricted rats that
did not, indicating direct lipogenic effects of OLZ. Our findings
were supported by a recent long-term study in male rats, where 40
days of treatment with constant doses (in the range of 2.5–10 mg/
kg) of several antipsychotics, including OLZ, elevated postprandial
serum TG relative to control, without concomitant increase in
body weight [22]. In addition, clinical findings of BMI-indepen-
dent serum TG increase have been described both in patients
treated with CLZ [24] and OLZ [25].
In the present study, we aimed to investigate the effect of the
lipid-lowering fatty acid analogue tetradecylthioacetic acid (TTA)
on antipsychotic-induced metabolic adverse effects. TTA, a pan-
peroxisome proliferator-activated receptor (PPAR) agonist target-
ing mitochondria, has been demonstrated to reduce body weight
gain, adiposity and serum lipids in male rats fed a high-fat diet
[26,27] and to exert lipid-lowering effects both in type 2 diabetes
and psoriatic patients [28,29]. TTA is well tolerated in patients
[28,29], and may represent a novel candidate agent for
pharmacological intervention in antipsychotic-treated patients
with dyslipidemia. In the present study, we investigate the effect
of TTA on body weight, serum lipids and transcriptional changes
in peripheral tissues in female rats, both as monotherapy and in
combination with antipsychotic drugs.
Materials and Methods
Ethics Statement
All experiments were approved by and carried out in
accordance with the guidelines of the Norwegian Committee for
Experiments on Animals (‘‘Forsøksdyrutvalget’’, permit number
20102332), and care was taken to ensure minimal animal suffering
at all stages of the experiment.
Animals and Treatment Schemes
Rats were kept under standard conditions with an artificial
12:12-hour light/dark cycle (lights on: 08:00) and constant 48%
humidity. Animals were allowed access to tap water and free (ad
libitum) access to standard laboratory chow during the experimen-
tal period. Prior to decapitation, rats were anesthetized using
isoflurane. Trunk blood was collected in serum tubes, which were
left at 4uC for 25–30 minutes and centrifuged at 4uC for 10
minutes (3,000g) to extract serum. Tissue samples were frozen in
liquid nitrogen and stored at 280uC until analysis.
Subchronic (2-week) Experiment
All antipsychotics were purchased from Toronto Research
Chemicals, Inc. (Canada). All stated drug doses equal total amount
of drug administered per 24 hours. As previously described [23],
female Sprague-Dawley rats (n = 9) housed 3 per cage were
administered with vehicle (VEH) or OLZ 6 mg/kg by gavage
b.i.d. for 13 days, and sacrificed on day 14 after an overnight fast.
As a pilot study on TTA effects, two treatment groups not
described in our recent publication [23] were also included in this
subchronic experiment: a TTA monotherapy group (150 mg/kg),
and a group receiving OLZ (6 mg/kg) and TTA (150 mg/kg)
(OLZ-TTA).
Chronic (8-week) Experiment
Female Sprague-Dawley rats weighing 24064 g (mean6-
SEM) on the first day of treatment were housed individually.
Each animal, and chow in each cage, was weighed daily. Self-
administration of antipsychotics and TTA was achieved by
using peanut butter as a vehicle. Based on previous reports [30],
drug doses were lowered compared to the subchronic experi-
ment as the treatment period was extended, in order to
determine whether lowered doses over time would result in an
extended period of excessive weight gain. The following
treatment groups were included: VEH (peanut butter), OLZ
3 mg/kg, aripiprazole (APZ) 3 mg/kg, ziprasidone (ZPS) 3 mg/
kg; CLZ 5 mg/kg; TTA 200 mg/kg, OLZ 3 mg/kg+TTA
200 mg/kg, CLZ 5 mg/kg+TTA 200 mg/kg (n = 10 in the
VEH-treated group, n= 8 in all other groups). The total daily
drug doses were split into two separate administrations (9 am
and 2.30 pm). The duration of drug exposure was 55 days, and
animals were sacrificed on day 56 (8 weeks) after the initiation
of treatment. As in the subchronic experiment, the last drug
dose before sacrifice was administered 18–20 hours prior to
decapitation. All animals were fasted from 9 pm on the day
prior to euthanasia. In order to avoid potential effects of time of
day and the duration of fast previous to sacrifice, one animal
from each treatment group was sacrificed between 9 am and 11
am on 9 consecutive working days.
RNA Extraction, cDNA Synthesis and Real-time PCR
Tissue samples (,30 mg of liver tissue or ,100 mg of white
adipose tissue) were homogenized using a TissueLyser (Qiagen,
USA). RNA extraction and cDNA synthesis were performed as
previously described [23]. Primers were designed using PrimerEx-
press (Applied Biosystems, USA) or Primer3 [31]. Relative gene
expression levels were determined using the comparative DCt
method [32].
Lipid and Glucose Measurements and Fatty Acid
Composition Analysis in Serum and in Liver
Levels of TG, phospholipids, and cholesterol in serum and liver
were measured enzymatically on the Hitachi 917 system (Roche
Diagnostics, Germany), as previously described [23]. Liver lipids
were extracted by the method of Bligh & Dyer [23], evaporated
under N2 and re-dissolved in isopropanol before analysis. Fatty
acid composition was analysed by gas-liquid chromatography as
previously described [23].
Determination of Serum Drug Levels
Serum levels of OLZ, CLZ, APZ, and ZPS (data not shown for
the latter two) were determined by means of liquid chromatog-
raphy/mass spectrometry (LC–MS) at Department of Clinical
Pharmacology, St Olavs Hospital, Trondheim, Norway, as
previously described [23].
Hepatic Enzyme Activities
Frozen liver samples were homogenized and post-nuclear
fractions were prepared as formerly described [33]. The activity
Table 1. Serum levels of antipsychotic agents.
Subchronic Chronic
OLZ 0.2760.03 1.2460.54
OLZ-TTA 0.8360.28 0.4260.64
CLZ 0.1060.87
CLZ-TTA 0.2560.06
Fasting serum levels of antipsychotic agents, given in nM, after 2 or 8 weeks of
treatment, respectively.
doi:10.1371/journal.pone.0050853.t001
Chronic Effects of Antipsychotics and TTA in Rats
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of carnitine palmitoyltransferase (CPT)-II was measured using
palmitoyl-CoA and radiolabelled carnitine to yield butanol soluble
radiolabelled palmitoylcarnitine [34,35]. The specific activity of
peroxisomal fatty acyl-CoA oxidase (ACOX) was measured as
previously described [36,37].
Statistical Analysis
Food intake was analyzed using two-way repeated measures
ANOVA, with treatment as between-subject variable and time as
within-subject variable in both experiments. In the chronic
experiment, weeks were used as time variable instead of days,
avoiding excessive degrees of freedom. Body weight changes were
analyzed using the same method. In the 2-week (subchronic)
experiment, the analysis included 4 treatment groups (VEH, OLZ,
TTA, and OLZ-TTA), whereas the chronic experiment contained
8 treatment groups (VEH, APZ, ZPS, TTA, CLZ, CLZ-TTA,
OLZ, OLZ-TTA). Tukey’s post hoc test was applied in order to
determine all significant inter-group differences, while Dunnett’s
post hoc test was utilized when comparing all treatment groups
with VEH. To detect differences at specific time points throughout
the time-course, one-way ANOVA analysis with subsequent post-
hoc tests was performed. For all other comparisons, we used two-
sided Student’s t-test. P values #0.05 were considered statistically
significant. All tests were conducted with PASW Statistics Version
18 (PASW statistics; SPSS, USA).
Results
Serum Drug Levels
In both the subchronic and the chronic experiments, serum
levels of antipsychotic agents at the time of dissection, i.e. 18–20
hours after administration of the last drug dose, were in the lower
nM range (Table 1). No consistent effect of TTA on OLZ or CLZ
levels was observed across the two experiments (Table 1).
Impact of Subchronic Exposure to Antipsychotics and
TTA on Food Intake, Body Weight Gain and Serum Lipids
in Female Rats
In a subchronic experiment we investigated how 2 weeks of
treatment with the lipid-lowering agent TTA affected the
previously demonstrated OLZ-induced weight gain and serum
triglyceride increase in female rats [23], with published data from
Figure 1. Parameters measured during the subchronic experiment. a) daily food intake, b) daily cumulative weight gain, and c) and serum
levels of total cholesterol, triglycerides, liver total cholesterol and triglycerides at the 2-week end point of the subchornic experiment. VEH, vehicle,
TTA: tetradecylthioacetic acid, OLZ: olanzapine. * P#0.05 vs vehicle.
doi:10.1371/journal.pone.0050853.g001
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the OLZ treatment included here for comparison. Four treatment
groups were included in the analyses; 1) Vehicle (VEH), 2) TTA,
3) OLZ, and 4) a combination of OLZ and TTA (OLZ-TTA).
Repeated-measures two-way ANOVA analysis was performed on
average daily food intake (3 rats per cage) and individual daily
cumulative weight gain, with treatment and time as factors. A
significant main effect of treatment was evident for both food
intake [F(3, 8) = 16.30, p,0.01] (Figure 1A) and weight gain [F(3,
32) = 11.24, p,0.001] (Figure 1B), with a Tukey’s post hoc test
revealing a significant elevation (p.0.05) by OLZ, but not by
TTA, relative to vehicle. Concordantly, TTA reduced neither
food intake nor weight gain in the OLZ-TTA treatment group
relative to OLZ.
Even though effects of TTA on food intake and body weight
were negligible, we investigated whether lipid-lowering effects of
TTA were present. Indeed, subchronic TTA treatment signifi-
cantly (p,0.05) reduced serum cholesterol and phospholipid levels
relative to VEH, evident both in the TTA and in the OLZ-TTA
treatment groups. In contrast, TTA did not reduce serum
triglyceride (TG) or free fatty acid (FFA) levels. Furthermore,
serum lipid levels in the TTA-OLZ treatment group were not
significantly lower than in the OLZ treatment group, in which TG
levels were elevated relative to control. In the liver, TTA induced a
significant decrease in cholesterol levels, as well as a non-
significant trend towards decreased TG levels, evident both in
the TTA and in the OLZ-TTA treatment groups (Figure 1D).
Fatty Acid Composition in Serum and Liver after
Subchronic Treatment with OLZ and TTA
Despite moderate effects of TTA on total TG and FFA serum
levels, the lipid-lowering effects observed for cholesterol and
phospholipids suggested that the dose used for TTA (150 mg/kg)
was sufficient to induce effects in the female rat. To gain further
insight into how TTA affects fatty acid metabolism, we examined
the effect on fatty acid (FA) composition, i.e. levels and subspecies
of saturated FAs (SFAs), monounsaturated FAs (MUFAs) and
polyunsaturated FAs (PUFAs). Both OLZ and TTA affected the
amounts of major lipid species, both in serum and in the liver
(Tables 2 and 3). Of note, the lipid-lowering TTA and the
lipogenic OLZ induced similar effects on several lipid species,
particularly evident for MUFAs and specifically with respect to the
elevation of oleic acid (C18:1n-9) (Tables 2 and 3). TTA and OLZ
also had opposite effects on some lipid entities, such as the n-3
PUFAs EPA, DHA and DPA, which were reduced by TTA and
elevated or displayed a trend towards elevation by OLZ (Tables 2
and 3).
Drug-induced Transcriptional Alterations in Lipid
Metabolism Genes
The sterol regulatory element binding protein (SREBP) is a
master regulator of cholesterol and fatty acid biosynthesis [38],
previously demonstrated to be activated by antipsychotic drugs
[39,40,41]. OLZ-induced, SREBP-controlled lipogenic effects
have been observed both in cultured cells [39] and in vivo, i.e. in
white adipose tissue [23,42] and liver [12] in the rat. In order to
identify mechanisms by which OLZ and TTA affect serum and
liver lipid levels, we investigated transcriptional effects on genes
involved in lipid metabolism in the liver, but in the subchronic
experiment, transcriptional effects of OLZ in the liver were minor
(Table 4). The effects of TTA on lipogenic gene expression were
also moderate. However, a marked upregulation (mean%6SEM;
259669%, P,0.05) of Scd1, encoding the stearoyl-delta 9
desaturase (SCD1) that converts stearic acid (C18:0) to oleic acid
(C18:1n-9), was observed in the OLZ-TTA treatment group
(Table 4). In agreement with the cholesterol-lowering effect of
TTA, hepatic levels of Hmgcr, the rate-limiting step in cholesterol
biosynthesis, was downregulated both in the TTA (6569%,
P#0.05) and OLZ-TTA (3664%, P#0.001) treatment groups,
Table 2. Lipid subspecies in serum in the subchronic
experiment.
VEH TTA OLZ OLZ-TTA
Total FA 10060 10060 10060 10060
SFA 32,760,6 32,560,5 32,460,9 31,7±0,8** "
C16:0 14,560,9 15,5±1,1* 15,261,2 15,6±0,4**
C18:0 15,960,6 15,161,0 15,161,1 13,9±0,9*** "
MUFA 10,661,1 12,6±1,5** 12,1±1,6* 13,1±1,9**
C16:1n-7 0,860,1 0,760,1 1,060,3 1,0±0,3 "
C18:1n-9 6,660,8 9,1±1,3*** 8,1±1,2* 9,0±1,5**
PUFA n-3 9,260,7 7,2±0,5*** 10,361,1 8,5±1,7 "
C20:5n-3 (EPA) 1,960,4 0,9±0,1*** 2,160,6 1,260,9
C22:6n-3 (DHA) 5,760,5 5,0±0,5** 6,3±0,5* 5,560,6
C22:5n-3 (DPA) 0,960,1 0,7±0,1** 1,1±0,2** 0,9±0,2 "
PUFA n-6 47,061,1 46,061,5 44,9±2,4* 44,2±3,3*
C18:2n-6 (LA) 18,061,6 16,961,5 16,961,3 15,8±1,1**
C20:4n-6 (AA) 27,762,6 27,363,0 26,562,9 26,864,1
Data are given in % of total fatty acid content, and presented as mean%6SEM.
* P#0.05 vs vehicle.
**P#0.01 vs vehicle.
***P#0.001 vs vehicle.
{OLZ-TTA significantly different from TTA, with " P#0.05, "" P#0.01,
""" P#0.001.
doi:10.1371/journal.pone.0050853.t002
Table 3. Lipid subspecies in the liver in the subchronic
experiment.
VEH TTA OLZ OLZ+TTA
Total FA 10060 10060 10060 10060
SFA 36,960,6 36,660,7 36,960,6 36,560,8
C16:0 15,160,5 14,661,1 15,360,7 14,660,7
C18:0 20,260,8 20,661,4 20,160,8 20,461,0
MUFA 9,961,2 11,161,5 10,861,9 11,161,8
C16:1n-7 0,660,1 0,5±0,1* 0,860,3 0,7±0,3 "
C18:1n-9 6,760,9 8,1±1,4* 7,5±1,4* 8,0±1,4*
PUFA n-3 13,361,0 10,9±0,9*** 14,2±0,8 * 12,6±1,2 ""
C20:5n-3 (EPA) 1,260,2 0,5±0,1*** 1,360,4 0,760,6
C22:6n-3 (DHA) 10,060,8 9,0±1,0* 10,760,6 10,1±0,5 ""
C22:5n-3 (DPA) 1,360,2 1,0±0,1*** 1,460,2 1,2±0,2 ""
PUFA n-6 39,660,6 40,060,6 37,7±2,0* 37,8±2,4* "
C18:2n-6 16,861,0 14,8±1,0*** 14,9±1,0** 12,9±0,6**
"""
C20:4n-6 21,160,9 23,4±1,4** 21,162,0 23,1±2,4*
Data are given in % of total fatty acid content, and presented as mean%6SEM.
* P#0.05 vs vehicle.
**P#0.01 vs vehicle.
***P#0.001 vs vehicle.
{OLZ-TTA significantly different from TTA, with " P#0.05, "" P#0.01,
""" P#0.001.
doi:10.1371/journal.pone.0050853.t003
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but also in the OLZ treatment group (5667%, P#0.05), despite
no clear effect of OLZ on serum cholesterol levels. Srebf2, encoding
the SREBP2 transcription factor – the main regulator of
cholesterol biosynthesis genes – was significantly downregulated
in the OLZ-TTA treatment group (6066%, P#0.01), with a trend
towards downregulation in the TTA group (8063%, P= 0.06).
TTA has been suggested to mediate its lipid-lowering effect via
increased hepatic b-oxidation through PPARa-controlled tran-
scriptional activation [26,27]. We therefore investigated hepatic
expression levels of the PPARa-controlled genes Acox1, encoding
the rate-limiting step of peroxisomal fatty acid b-oxidation, and
Cpt2, involved in mitochondrial fatty acid oxidation. Hepatic Acox1
expression was significantly upregulated both in the TTA
treatment group (177621%, P#0.01) and, with a more pro-
nounced effect, in the OLZ-TTA treatment group (349641%,
P#0.001). A similar pattern was observed for Cpt2 (Table 4), albeit
reaching statistically significance (P,0.001) only in the OLZ-TTA
treatment group. OLZ monotherapy did not induce significant
effects on Acox1 or Cpt2.
Since lipase expression levels may contribute to alterations in
lipid levels, we measured drug effects on lipase genes, such as
adipose triglyceride synthase (Pnpla2/Atgl) and hormone-sensitive
lipase (Hsl), in visceral (parametrial) white adipose tissue (WAT).
However, with the exception of a slight OLZ-induced downreg-
ulation of Pnpla2 in parametrial WAT, no significant alterations
were observed.
Long-term Effects of Antipsychotics and TTA on Food
Intake, Body Weight and Lipid Parameters
TTA-induced effects are typically more evident after long-
term than after subchronic treatment [26]. The moderate effects
observed in our subchronic experiment may thus be due to lack
of sufficient exposure time and/or dosage. The effect of a
moderately higher TTA dose on metabolic parameters in female
rats was therefore investigated in a chronic setting. Weight-
inducing effects of long-term antipsychotic treatment normally
follows an opposite pattern in rat, with declining rates of weight
gain in the long-term setting [30,43]. However, in light of the
weight-independent elevation of serum triglycerides recently
shown after chronic treatment in male rats, female rats were
treated chronically (8 weeks) with either atypical antipsychotic
drugs (OLZ, CLZ, APZ, or ZPS), TTA, or TTA in
combination with the orexigenic atypical antipsychotics OLZ
or CLZ (OLZ-TTA, CLZ-TTA). As expected, the effect of
antipsychotic drugs on food intake and weight gain was most
prominent during the first weeks of treatment, followed by a
decline, with resultant lack of significant differences in total
cumulative weight gain at the experiment’s 8-week end point.
However, a two-way repeated-measures ANOVA analysis for
the entire treatment period (8 weeks), with treatment and time
(with weeks replacing days in order to avoid excessive degrees of
freedom) as factors, revealed a statistically significant main effect
of treatment on cumulative weekly food intake [F(4,58) = 3.66,
P#0.01] and cumulative weekly weigh gain [F(7,58) = 3.78,
P,0.01]. Dunnett’s post-hoc tests revealed significant effects
with respect to food intake for OLZ (P#0.05) (Figure 2C) and
OLZ-TTA (P#0.01) (Figure 2D), as well as a trend towards
statistically significant effect for APZ (P= 0.10) (data not shown),
relative to VEH-treated controls. With respect to weight gain,
Dunnets’ post-hoc test revealed only the OLZ-TTA treatment
group as significantly (P#0.01) different from VEH. According-
ly, analysing each time point separately by a one-way ANOVA,
the only significant increase in weight gain at the late time
points occured in the OLZ-TTA treatment group relative to
VEH (Figure 3D). It should also be noted that there seems to
be a clear trend towards potentiation of body weight gain in the
co-treatment groups OLZ-TTA and CLZ-TTA relative to the
OLZ and CLZ monotherapy groups (Figure 3C-F), although
Tukeys’ post-hoc test revealed no significant effects.
In the chronic setting, the lipid-lowering effects of TTA were
much more evident than in the subchronic setting, with marked
reduction of trends towards reduction for all major lipid classes,
both in liver and in serum (Figure 4). Quite the opposite, none of
the antipsychotic drugs significantly altered the levels of any serum
or liver lipid classes (Figure 4). Despite the lack of antipsychotic-
induced effects, the effects of TTA on serum TG in the co-
treatment groups (OLZ-TTA and CLZ-TTA) were more
pronounced than in the monotherapy groups, reminiscent of
TTA’ potentiating effect on weight gain in OLZ-treated rats.
Transcriptional Changes in the Liver
Like in the subchronic setting, only minor hepatic lipogenic
transcriptional alterations were observed for the antipsychotic
drugs, with a trend towards downregulation for both SREBP1 and
SREBP2 targets genes (Table 5). TTA also had negligible effects
on SREBP1 target genes in the liver, with the exception of Scd1,
which was strikingly upregulated in all TTA treatment groups
(Table 5). Reminiscent of the subchronic setting, TTA induced
downregulation of SREBP2-controlled cholesterol biosynthesis
genes. TTA’s stimulatory effect on the transcription of PPARa and
Table 4. Selected genes with drug exposure-related, differential expression in liver in the subchronic experiment.
Scd1 Fasn Srebp1 Hmgcr Srebp2 Ppara Pparg Cpt2 Acox1
VEH [23] 1.0060.28 1.0060.12 1.0060.33 1.0060.14 1.0060.09 1.0060.14 1.0060.13 1.0060.11 1.0060.09
TTA 1.3560.24 0.9760.15 1.47±0.07** 0.65±0.09* 0.8060.03 1.0160.08 0.7660.08 1.2760.32 1.77±0.21**
OLZ [23] 1.2560.39 0.8860.14 0.7560.13 0.56±0.07** 0.8260.10 0.7460.1 0.7260.09 0.9260.30 0.9560.11
OLZ-TTA 2.59±0.69* 0.6560.11 0.7560.1 0.36±0.04*** 0.60±0.06** 0.9060.04 0.7460.1 2.08±0.35*** 3.49±0.41***
Data are given as fold change relative to vehicle, and presented as mean6SEM. Data shown are normalised to P0 (Arbp), with comparable results when normalised to b-
actin.
*P#0.05 vs vehicle.
**P#0.01 vs vehicle.
***P#0.001 vs vehicle. Subchronic data for the VEH, OLZ, and APZ groups have been reported in a previous article [23]. Gene abbreviations: Scd1; stearoyl-CoA
desaturase. Fasn; fatty acid synthase. Srebp1; sterol regulatory element binding protein 1, Srebp2; sterol regulatory element binding protein 2. Hmgcr; 3-hydroxy-3-
methylglutaryl-CoA reductase. Ppara: peroxisome proliferator activated receptor a, Pparg: peroxisome proliferator activated receptor c. Cpt2: carnitine O-
palmitoyltransferase 2. Acox1: acyl-Coenzyme A oxidase 1.
doi:10.1371/journal.pone.0050853.t004
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Figure 2. Daily food intake during 8 weeks of treatment with antipsychotics and TTA. Total food intake during the entire treatment period
of 8 weeks (a) and daily food intake during chronic treatment with vehicle (open circles), antipsychotic monotherapy, TTA, or antipsychotics in
combination with TTA (filled circles; b-f). Data are given as mean6SEM. * P#0.05 vs vehicle (Dunnett’s post hoc test for daily food intake). TTA:
tetradecylthioacetic acid, OLZ: olanzapine, CLZ: clozapine.
doi:10.1371/journal.pone.0050853.g002
Chronic Effects of Antipsychotics and TTA in Rats
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Figure 3. Daily, cumulative weight gain during 8 weeks of treatment with antipsychotics and TTA. Total weight gain during the entire
treatment period of 8 weeks (a) and daily cumulative weight gain during chronic treatment with vehicle (open circles), antipsychotic monotherapy,
TTA, or antipsychotics in combination with TTA (filled circles; b-f). Data are given as mean6SEM. * P#0.05 vs vehicle (Dunnett’s post hoc test for daily
cumulative weight gain). TTA: tetradecylthioacetic acid, OLZ: olanzapine, CLZ: clozapine.
doi:10.1371/journal.pone.0050853.g003
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Figure 4. Fasting lipids in serum and liver at 8 weeks. Serum and liver lipids after chronic treatment with vehicle (VEH), olanzapine (OLZ),
clozapine (CLZ), tetradecylthioacetic acid (TTA), or a combination of OLZ/CLZ+TTA. * P#0.05, ** P#0.01, *** P#0.001.
doi:10.1371/journal.pone.0050853.g004
Table 5. Selected genes with drug exposure-related, differential expression in liver in the chronic experiment.
Scd1 Fasn Srebp1 Hmgcr Srebp2 Ppara Pparg Cpt2 Acox1
VEH 1.0060.36 1.0060.26 1.0060.09 1.0060.14 1.0060.11 1.0060.07 1.0060.10 1.0060.10 1.0060.10
TTA 2.22±0.36* 0.9760.20 1.0860.18 0.57±0.06** 0.8460.12 1.1460.11 1.77±0.21** 1.38±0.09** 2.23±0.30***
OLZ 1.1560.17 0.7060.16 0.58±0.06*** 0.7860.09 0.8660.08 1.2160.13 1.0560.12 0.9260.06 0.9360.08
OLZ-
TTA
2.73±0.76* 0.8160.12 1.57±0.15** 0.55±0.09* 0.44±0.05*** 0.9160.12 2.51±0.37*** 1.55±0.11*** 3.39±0.47***
CLZ 1.5760.98 0.6060.10 0.7760.15 0.9060.27 0.7360.11 1.41±0.13** 1.2060.23 0.9360.07 0.8260.12
CLZ-
TTA
2.74±0.47** 0.5760.10 1.1260.14 0.50±0.08** 0.51±0.07*** 1.39±0.17* 2.10±0.19*** 1.83±0.11*** 2.47±0.34***
APZ 0.6060.20 0.4460.07 0.70±0.10* 0.43±0.04*** 0.7760.07 1.33±0.16* 1.0760.22 0.73±0.05* 0.64±0.06*
ZPS 1.5560.74 0.5760.10 0.50±0.07*** 0.9960.14 0.9260.12 1.2960.18 1.0760.13 1.0160.12 0.9060.18
Data are given as fold change relative to vehicle, and presented as mean6SEM. Data shown are normalised to P0 (Arbp), with comparable results when normalised to b-
actin.
*P#0.05 vs vehicle.
**P#0.01 vs vehicle.
***P#0.001 vs vehicle. For abbreviations, see legend to Table 3.
doi:10.1371/journal.pone.0050853.t005
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its target genes in the liver was also maintained in the chronic
setting, with significant upregulation of Acox1 after treatment with
TTA (222630%, P#0.001), OLZ-TTA (339647%, P#0.001)
and, furthermore, in the CLZ-TTA group (247634%, P#0.001)
(Table 5). Corresponding transcriptional effects were observed for
Cpt2 expression (Table 5). Enzymatic activity corroborated the
transcriptional changes (Figure S1).
Transcriptional Alterations in White and Brown Adipose
Tissues
In contrast to the pronounced OLZ-induced transcriptional
activation of lipogenic genes observed in visceral WAT in the
subchronic setting, hypothesized by us to be of relevance to the
observed increase in serum TG levels [23], chronic exposure
induced only minor transcriptional effects in parametrial WAT.
Of note, Scd1 was significantly downregulated by OLZ (29612%,
P#0.05) and a trend towards downregulation was observed in the
OLZ-TTA treatment group (4069%, P=0.09), demonstrating
opposite effects to what we observed in the subchronic setting. No
significant effects were observed for TTA monotherapy. The
expression of key lipase genes ((Pnpla2/Atgl and Hsl) was unaffected
in WAT in the chronic experiment (data not shown).
In order to investigate whether reduced energy expenditure
could contribute to the observed differences, or trends towards
differences, in weight gain between some of the treatment groups,
we examined brown adipose tissue (BAT) expression levels of
several thermogenic markers, among them peroxisome prolifera-
tive activated receptor gamma coactivator 1 alpha (PGC1a,
encoded by Ppargc1a) and uncoupling protein 1 (Ucp1). In the
subchronic experiment, TTA monotherapy did not have signifi-
cant effects on the expression of key thermogenic markers in BAT
(Table 6), while OLZ treatment downregulated Ppargc1a and Ucp1,
an effect that was reflected in the OLZ-TTA group. After chronic
treatment, Ppargc1a downregulation was observed both in animals
receiving TTA and in the OLZ-TTA group, but not in the OLZ
group (Table 7).
Discussion
In this study, we evaluated the modified fatty acid TTA as a
potential pharmacologic intervention strategy for metabolic
adverse effects of antipsychotic agents, primarily the metabolically
potent drugs OLZ and CLZ. TTA was initially examined in a
subchronic (two-week) experiment, as OLZ had previously been
shown to induce weight gain and elevated fasting triglyceride levels
in female rats within this time frame [23]. Two weeks of TTA
exposure reduced serum cholesterol and phospholipid levels in
female rats, but had no effect on serum TG or FFA levels. More
importantly, TTA failed to prevent weight gain and elevated
serum TG levels induced by subchronic OLZ exposure. However,
it should be noted that metabolically relevant effects of pharma-
cological agents do not necessarily depend on absolute amounts of
lipids, but also on lipid composition [44]. Interestingly, despite the
fact that TTA did not reduce absolute levels of serum TG and
FFA in the subchronic setting, the amounts of several fatty acid
subspecies were affected by TTA. Such effects were also observed
for OLZ, with differential effects of TTA and OLZ on some lipid
subspecies, e.g. n-3 PUFAs, but with comparable effects on other
FAs, such as MUFAs. For instance, both TTA and OLZ increased
serum levels of the delta-9-desaturase product oleic acid (C18:1n-
9) and decreased its precursor stearic acid (C18:0), in line with
previous studies demonstrating increased 18:1/18:0 ratio both for
OLZ [22], the second-generation antipsychotic risperidone [45]
and TTA [46]. The 18:1/18:0 ratio is an index of increased
activity of stearoyl CoA (delta-9) desaturase (SCD1) [47,48],
encoded by the SREBP1 target gene Scd1.
Despite the elevated 18:1/18:0 ratio, Scd1 expression was not
significantly increased by TTA or OLZ monoterapy, while
significantly elevated in the OLZ-TTA treatment group. This
effect was not observed for any of the other SREBP1-controlled
fatty acid biosynthesis genes, suggesting that the effect on Scd1
expression was mediated by mechanisms additional to SREBP
activation. Indeed, Scd1 has also been classified as a PPARa-target
gene [49], and it is possible that the Scd1 upregulation observed in
in our experient results from a combination of SREBP1 and
PPARa activation. It should be noted that the presence of elevated
18:1/18:0 ratio with concomitant lack of elevated Scd1 expression
in the liver was also observed after chronic treatment with OLZ
[22].
The lack of TTA effects on total TG and FFA serum levels
following subchronic exposure in female rats contrasts previous
studies in male rats [26], likely due to the relatively short duration
of treatment. We therefore investigated the effect of TTA in
female rats in a chronic (8-week) setting. Indeed, the increased
duration of treatment had significant effects on several parameters,
with reduced lipid levels, including TG and FFA, in all treatment
groups that included TTA (TTA, OLZ-TTA and CLZ-TTA),
apparently with more pronounced lipid-lowering effects of TTA in
Table 6. Relevant genes examined in brown adipose tissue
(BAT) in the subchronic study.
Ppargc1a Ppargc1b Ucp1 Ucp3 Ppara
VEH [23] 160.20 160.09 160.16 160.12 160.06
TTA 0.8560.23 1.2060.07 0.7960.11 1.1960.14 1.1860.04
OLZ [23] 0.41±0.10* 1.1860.09
0.49±0.04** 0.9060.05 1.3360.15
OLZ-TTA 0.30±0.05** 1.0860.08 0.57±0.08* 1.1860.20 0.9660.06
Data are given as fold change relative to vehicle, and presented as mean6SEM.
Data shown are normalised to P0 (Arbp), with comparable results when
normalised to b-actin.
*P#0.05 vs vehicle.
**P#0.01 vs vehicle.
***P#0.001 vs vehicle.
doi:10.1371/journal.pone.0050853.t006
Table 7. Relevant genes examined in brown adipose tissue
(BAT) in the chronic study.
Pgc1a Pgc1b Ucp1 Ucp3 Ppara
VEH 160.14 160.11 160.18 160.13 160.11
TTA 0.63±0.08* 0.9060.09 0.48±0.07* 0.8760.16 0.9060.09
OLZ 0.7660.24 0.8560.06 0.5360.08 0.8760.07 0.8560.06
OLZ-TTA 0.34±0.04*** 0.8360.08 0.9860.19 0.9860.09 1.0060.08
CLZ 0.4660.09 1.0160.08 1.2660.17 1.3360.10 0.8360.08
CLZ-TTA 0.6660.26 0.8560.05 0.8560.14 0.9160.09 0.8560.05
APZ 0.6260.13 0.9660.03 1.0460.21 0.9560.06 0.9660.03
Data are given as fold change relative to vehicle, and presented as mean6SEM.
Data shown are normalised to P0 (Arbp), with comparable results when
normalised to b-actin.
*P#0.05 vs vehicle.
**P#0.01 vs vehicle.
***P#0.001 vs vehicle.
doi:10.1371/journal.pone.0050853.t007
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the co-treatment groups. Such a co-treatment effect was also
evident for weight gain, with a trend towards elevated weight gain
in OLZ-TTA and CLZ-TTA treatment groups relative to OLZ
and CLZ groups, respectively. At first glance, the co-occurrence of
the potentiated weight gain and serum lipid reduction in the
antipsychotic-TTA co-treatment groups may seem paradoxical.
However, according to the adipose tissue expandability hypothesis,
metabolically unfavourable effects on serum lipid levels is not an
inevitable consequence of obesity [50]. In fact, up to a certain
threshold, expanding WAT tissue mass may provide storage
capacity for lipids, thus reducing serum lipid levels [50]. In line
with this, a genetically induced increase in WAT storage capacity
in mice has been shown to lead to a healthy serum lipid profile,
despite massive weight gain [51]. Whether this phenomenon
occurred in our experiment remains uncertain, since only
negligible alterations in the expression of lipid biosynthesis and
storage genes, none of which indicated increased lipid storage
capacity, were observed in WAT.
Although time-dependent decline of OLZ-induced hyperphagia
and weight gain in the rat has previously been described
[16,30,43], the lack of dyslipidemic effects in chronically exposed
rats contrasted our subchronic findings as well as a recent chronic
study in male rats, where postprandial serum TG levels were
elevated after 40 days of treatment with OLZ as well as other
antipsychotics [22]. Gender-specific effects may partially account
for the observed differences, possibly with gradual tolerance
towards antipsychotics in female rats. If so, this effect seems to be
specific to antipsychotic drugs, since the effects of TTA were more
pronounced after eight than after two weeks of treatment in female
rats. Differing nutritional status (fasted vs. postprandial) is another
important distinction between the two chronic studies. Finally, it
should be noted that during the last two weeks of our experiment,
weight gain surged in VEH-treated female rats, possibly occluding
other antipsychotic-induced metabolic adverse effects. The pro-
nounced lipid-lowering effect of TTA found in the OLZ-TTA and
the CLZ-TTA treatment groups is promising with respect to the
potential role of TTA in preventing antipsychotic-induced
hyperlipidemia. As the antipsychotic drugs induced neither weight
gain nor dyslipidemic effects in the chronic setting, however, no
firm conclusion can be drawn regarding TTA’s potential clinical
value at this point. An optimized model for antipsychotic-induced
dyslipidemia is warranted to conclude about the lipogenic effects
of atipsychotics, as well as potential clinical benefits of TTA.
The trends towards more pronounced effects on metabolic
parameters in the antipsychotic-TTA treatment groups, as
observed for serum lipids, was also evident with respect to body
weight gain and to alterations in gene expression. The mechanisms
underlying these add-on effects are unclear. Reduced thermogenic
activity in BAT, previously demonstrated in OLZ-treated rats
[52], may be of relevance for the observed metabolic changes.
Indeed, the expression levels of the thermogenic marker Ucp1 was
reduced in both the OLZ and TTA monotherapy groups, but not
in the co-tratment group, failing to provide an explanation for the
potentiated weight gain in this group. Although TTA had no
consistent effect on OLZ and CLZ serum levels, it is tempting to
speculate that TTA may increase the bioavailability of antipsy-
chotics in the rat through altering the drugs’ pharmacokinetics or
other aspects of antipsychotic turnover in the body. In humans,
OLZ and CLZ are primarily metabolized by CYP1A2 [53], which
does not play an important role in the metabolism of TTA [54].
Thus, the theoretical basis of inhibition or induction of antipsy-
chotic metabolism by TTA is not present, but no experimental
evidence presently exists in this regard. TTA may still affect
pharmacodynamic aspects of antipsychotic drug metabolism, such
as tissue distribution.
In conclusion, based on the marked lipid-lowering effects of
TTA in female rats, particularly evident when co-treated with the
orexigenic antipsychotic drugs OLZ and CLZ in a chronic setting,
the potential of TTA as a candidate for pharmacological
intervention of antipsychotic-induced dyslipidemic effects is
present. However, in order to make firm conclusions, a refined
rodent model for antipsychotic-induced dyslipidemia must be
available, along with an improved understanding of how factors
such as gender, nutritional status, mode of drug administration
and drug doses affect the phenotype. Our findings lend further
support to the notion that antipsychotic-induced weight gain and
dyslipidemia may occur independently, which should be taken into
account when treatment regimes for metabolic disturbances is
developed.
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** P#0.01, *** P#0.001. " P#0.05 vs TTA, "" P#0.01 vs TTA.
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